These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 21150651)

  • 1. Improvement in growth of children with Crohn disease following anti-TNF-α therapy can be independent of pubertal progress and glucocorticoid reduction.
    Malik S; Wong SC; Bishop J; Hassan K; McGrogan P; Ahmed SF; Russell RK
    J Pediatr Gastroenterol Nutr; 2011 Jan; 52(1):31-7. PubMed ID: 21150651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
    Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
    Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of recombinant human growth hormone on linear growth in children with Crohn's disease and short stature.
    Wong SC; Hassan K; McGrogan P; Weaver LT; Ahmed SF
    J Pediatr Endocrinol Metab; 2007 Dec; 20(12):1315-24. PubMed ID: 18341091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infliximab improves inflammation and anthropometric measures in pediatric Crohn's disease.
    Sinitsky DM; Lemberg DA; Leach ST; Bohane TD; Jackson R; Day AS
    J Gastroenterol Hepatol; 2010 Apr; 25(4):810-6. PubMed ID: 20492339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Growth abnormalities persist in newly diagnosed children with crohn disease despite current treatment paradigms.
    Pfefferkorn M; Burke G; Griffiths A; Markowitz J; Rosh J; Mack D; Otley A; Kugathasan S; Evans J; Bousvaros A; Moyer MS; Wyllie R; Oliva-Hemker M; Carvalho R; Crandall W; Keljo D; Walters TD; LeLeiko N; Hyams J
    J Pediatr Gastroenterol Nutr; 2009 Feb; 48(2):168-74. PubMed ID: 19179878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disease Status and Pubertal Stage Predict Improved Growth in Antitumor Necrosis Factor Therapy for Pediatric Inflammatory Bowel Disease.
    Cameron FL; Altowati MA; Rogers P; McGrogan P; Anderson N; Bisset WM; Ahmed SF; Wilson DC; Russell RK
    J Pediatr Gastroenterol Nutr; 2017 Jan; 64(1):47-55. PubMed ID: 27657882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease.
    Martínez-Borra J; López-Larrea C; González S; Fuentes D; Dieguez A; Deschamps EM; Pérez-Pariente JM; López-Vázquez A; de Francisco R; Rodrigo L
    Am J Gastroenterol; 2002 Sep; 97(9):2350-6. PubMed ID: 12358255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of infliximab in the treatment of Crohn's disease in children and adolescents.
    Hyams JS; Markowitz J; Wyllie R
    J Pediatr; 2000 Aug; 137(2):192-6. PubMed ID: 10931411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism.
    Louis E; Vermeire S; Rutgeerts P; De Vos M; Van Gossum A; Pescatore P; Fiasse R; Pelckmans P; Reynaert H; D'Haens G; Malaise M; Belaiche J
    Scand J Gastroenterol; 2002 Jul; 37(7):818-24. PubMed ID: 12190096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Etanercept treatment improves longitudinal growth in prepubertal children with juvenile idiopathic arthritis.
    Vojvodich PF; Hansen JB; Andersson U; Sävendahl L; Hagelberg S
    J Rheumatol; 2007 Dec; 34(12):2481-5. PubMed ID: 18050366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inflixmab as a possible treatment for the hemorrhagic type of Crohn's disease.
    Tsujikawa T; Nezu R; Andoh A; Saotome T; Araki Y; Ishizuka Y; Sasaki M; Koyama S; Fujiyama Y
    J Gastroenterol; 2004; 39(3):284-7. PubMed ID: 15065007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease.
    Gao Q; Hogezand RA; Lamers CB; Verspaget HW
    Aliment Pharmacol Ther; 2004 Sep; 20(5):585-92. PubMed ID: 15339330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-Saccharomyces cerevisiae antibodies and response to infliximab in refractory Crohn's disease.
    Schröder O; Naumann M; Stein J
    Aliment Pharmacol Ther; 2004 Oct; 20(7):823-4. PubMed ID: 15379845
    [No Abstract]   [Full Text] [Related]  

  • 14. Complications of infliximab therapy in children and adolescents affected by Crohn's disease.
    Diamanti A; Papadatou B; Knafelz D; Gambarara M; Ferretti F; Castro M
    Am J Gastroenterol; 2003 Dec; 98(12):2812-3. PubMed ID: 14687847
    [No Abstract]   [Full Text] [Related]  

  • 15. Therapeutic efficacy of infliximab on patients with short duration of Crohn's disease: a Japanese multicenter survey.
    Matsumoto T; Iida M; Motoya S; Haruma K; Suzuki Y; Kobayashi K; Ito H; Miyata M; Kusunoki M; Chiba T; Yamamoto S; Hibi T
    Dis Colon Rectum; 2008 Jun; 51(6):916-23. PubMed ID: 18322754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maintenance infliximab treatment is associated with improved bone mineral density in Crohn's disease.
    Bernstein M; Irwin S; Greenberg GR
    Am J Gastroenterol; 2005 Sep; 100(9):2031-5. PubMed ID: 16128948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The duration of effect of infliximab maintenance treatment in paediatric Crohn's disease is limited.
    De Bie CI; Hummel TZ; Kindermann A; Kokke FT; Damen GM; Kneepkens CM; Van Rheenen PF; Schweizer JJ; Hoekstra JH; Norbruis OF; Tjon A Ten WE; Vreugdenhil AC; Deckers-Kocken JM; Gijsbers CF; Escher JC; De Ridder L
    Aliment Pharmacol Ther; 2011 Jan; 33(2):243-50. PubMed ID: 21083595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort.
    Schnitzler F; Fidder H; Ferrante M; Noman M; Arijs I; Van Assche G; Hoffman I; Van Steen K; Vermeire S; Rutgeerts P
    Gut; 2009 Apr; 58(4):492-500. PubMed ID: 18832518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease.
    Suenaert P; Bulteel V; Lemmens L; Noman M; Geypens B; Van Assche G; Geboes K; Ceuppens JL; Rutgeerts P
    Am J Gastroenterol; 2002 Aug; 97(8):2000-4. PubMed ID: 12190167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.
    Hyams J; Crandall W; Kugathasan S; Griffiths A; Olson A; Johanns J; Liu G; Travers S; Heuschkel R; Markowitz J; Cohen S; Winter H; Veereman-Wauters G; Ferry G; Baldassano R;
    Gastroenterology; 2007 Mar; 132(3):863-73; quiz 1165-6. PubMed ID: 17324398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.